BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $101,160,905 | -42.9% | 2,680,470 | -31.1% | 0.02% | -42.9% |
| Q2 2023 | $177,201,394 | +79.1% | 3,889,408 | +59.4% | 0.04% | +66.7% |
| Q1 2023 | $98,948,684 | +70.9% | 2,439,564 | +114.8% | 0.02% | +61.5% |
| Q4 2022 | $57,897,006 | -8.9% | 1,135,904 | -3.7% | 0.01% | -13.3% |
| Q3 2022 | $63,521,000 | -32.0% | 1,179,376 | -18.9% | 0.02% | -28.6% |
| Q2 2022 | $93,443,000 | -25.2% | 1,454,822 | -9.7% | 0.02% | -19.2% |
| Q1 2022 | $124,932,000 | -2.6% | 1,611,206 | +7.9% | 0.03% | 0.0% |
| Q4 2021 | $128,221,000 | +12.1% | 1,493,725 | +5.0% | 0.03% | +8.3% |
| Q3 2021 | $114,366,000 | -7.8% | 1,421,933 | -7.7% | 0.02% | -14.3% |
| Q2 2021 | $124,058,000 | -2.9% | 1,541,104 | +1.7% | 0.03% | -12.5% |
| Q1 2021 | $127,778,000 | +11.6% | 1,515,033 | +6.2% | 0.03% | +10.3% |
| Q4 2020 | $114,483,000 | +15.4% | 1,426,751 | +15.7% | 0.03% | +3.6% |
| Q3 2020 | $99,186,000 | -35.5% | 1,233,346 | -31.0% | 0.03% | -40.4% |
| Q2 2020 | $153,893,000 | -8.8% | 1,787,376 | -14.0% | 0.05% | -21.7% |
| Q1 2020 | $168,674,000 | -23.0% | 2,077,535 | -20.7% | 0.06% | +7.1% |
| Q4 2019 | $219,011,000 | +1.8% | 2,619,133 | +6.5% | 0.06% | -9.7% |
| Q3 2019 | $215,132,000 | +20.1% | 2,459,487 | +12.5% | 0.06% | +21.6% |
| Q2 2019 | $179,124,000 | -0.2% | 2,187,100 | -0.9% | 0.05% | -5.6% |
| Q1 2019 | $179,517,000 | +19.5% | 2,207,809 | -3.2% | 0.05% | +12.5% |
| Q4 2018 | $150,162,000 | -32.4% | 2,281,396 | -20.8% | 0.05% | -17.2% |
| Q3 2018 | $221,990,000 | +10.7% | 2,879,615 | +6.1% | 0.06% | +7.4% |
| Q2 2018 | $200,492,000 | -40.9% | 2,715,231 | -48.0% | 0.05% | -37.9% |
| Q1 2018 | $339,287,000 | +1.6% | 5,216,599 | +0.9% | 0.09% | +8.8% |
| Q4 2017 | $334,054,000 | -12.3% | 5,167,915 | -14.8% | 0.08% | -14.0% |
| Q3 2017 | $380,710,000 | -1.1% | 6,067,115 | -4.6% | 0.09% | -6.1% |
| Q2 2017 | $385,086,000 | +29.3% | 6,360,860 | +10.8% | 0.10% | +22.2% |
| Q1 2017 | $297,835,000 | +27.5% | 5,743,031 | +9.0% | 0.08% | +22.7% |
| Q4 2016 | $233,542,000 | -3.8% | 5,267,072 | +3.3% | 0.07% | -9.6% |
| Q3 2016 | $242,761,000 | +71.9% | 5,099,995 | +63.3% | 0.07% | +58.7% |
| Q2 2016 | $141,216,000 | +32.7% | 3,122,874 | +20.6% | 0.05% | +31.4% |
| Q1 2016 | $106,379,000 | -16.0% | 2,589,540 | -22.0% | 0.04% | -10.3% |
| Q4 2015 | $126,581,000 | +7.7% | 3,317,979 | -7.3% | 0.04% | -2.5% |
| Q3 2015 | $117,582,000 | -80.1% | 3,579,356 | -57.7% | 0.04% | -78.1% |
| Q2 2015 | $591,852,000 | +245.5% | 8,463,474 | +238.4% | 0.18% | +238.9% |
| Q1 2015 | $171,310,000 | +12.3% | 2,500,881 | +20.2% | 0.05% | +12.5% |
| Q4 2014 | $152,546,000 | +12.4% | 2,081,408 | +10.1% | 0.05% | +9.1% |
| Q3 2014 | $135,735,000 | -27.1% | 1,891,251 | -26.6% | 0.04% | -24.1% |
| Q2 2014 | $186,177,000 | -21.3% | 2,575,074 | -19.9% | 0.06% | -25.6% |
| Q1 2014 | $236,501,000 | +8.0% | 3,214,198 | +2.1% | 0.08% | +8.3% |
| Q4 2013 | $218,960,000 | +43.5% | 3,148,230 | +35.5% | 0.07% | +26.3% |
| Q3 2013 | $152,586,000 | -29.9% | 2,322,815 | -26.0% | 0.06% | -32.1% |
| Q2 2013 | $217,525,000 | -10.5% | 3,140,263 | -13.9% | 0.08% | -16.0% |
| Q4 2012 | $243,042,000 | +36.6% | 3,645,983 | +23.5% | 0.10% | +40.8% |
| Q3 2012 | $177,868,000 | +87.8% | 2,951,183 | +65.7% | 0.07% | +69.0% |
| Q2 2012 | $94,691,000 | -55.4% | 1,781,577 | -49.8% | 0.04% | -57.6% |
| Q1 2012 | $212,168,000 | – | 3,549,138 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |